Effect of obesity on fragility fractures, BMD and vitamin D levels in postmenopausal women. Influence of type 2 diabetes mellitus.

AIMS: To see the effects of obesity on risk fracture, bone density (BMD), and vitamin D levels in a group of postmenopausal women, and consider how comorbid type 2 diabetes mellitus (T2DM) modifies them. METHODS: 679 postmenopausal women were grouped into obese and non-obese. Obese women were grouped into those with T2DM and those without. 25(OH)-vitamin D, PTH and BMD were measured, and prevalent fragility fractures were gathered. RESULTS: Obese women had higher prevalence of T2DM, than non-obese women. Levels of 25(OH)-vitamin D were lower and those of PTH higher in obese women, BMD values were higher in obese women. Diabetic-obese women had a higher prevalence of non-vertebral fractures than non-diabetic-obese. Multivariate logistic regression model showed association of fragility fractures with age, total hip BMD, BMI and T2DM. Obese women have higher BMD and lower 25(OH)-vitamin D values (and higher PTH) than non-obese, without diabetes. CONCLUSIONS: T2DM confers an increased risk of non-vertebral fractures in postmenopausal obese women.

How can the orthopedic surgeon ensure optimal vitamin D status in patients operated for an osteoporotic fracture?

In this narrative review, the role of vitamin D deficiency in the pathophysiology, healing of fragility fractures, and rehabilitation is discussed. Vitamin D status can be assessed by measuring serum 25(OH)-vitamin D level with standardized assays. There is a high prevalence of vitamin D insufficiency (25(OH)D < 50 nmol/l (i.e., 20 ng/mL)) or deficiency (25(OH)D < 25 nmol/l (i.e., 10 ng/mL)) in patients with fragility fractures and especially in those with a hip fracture. The evidence on the effects of vitamin D deficiency and/or vitamin D supplementation on fracture healing and material osseointegration is still limited. However, it appears that vitamin D have a rather positive influence on these processes. The fracture liaison service (FLS) model can help to inform orthopedic surgeons, all caregivers, and fractured patients about the importance of optimal vitamin D status in the management of patients with fragility fractures. Therefore, vitamin D status should be included in Capture the Fracture® program as an outcome of FLS in addition to dual-energy X-ray absorptiometry (DXA) and specific antiosteoporosis medication. Vitamin D plays a significant role in the pathophysiology and healing of fragility fractures and in rehabilitation after fracture. Correction of vitamin D deficiency should be one of the main outcomes in fracture liaison services.

Profile of patients who consult with internists for an osteoporosis assessment: The OSTEOMED registry.

BACKGROUND AND OBJECTIVES: Osteoporosis is considered a generalised skeletal disorder in which there is impaired bone resistance, which predisposes the individual to a greater risk of fracture. The aim of this cross-sectional study was to collect and present data on the main clinical characteristics of patients who consult medical internists in Spain. Understanding these characteristics can help in implementing action plans to improve these patients' care more effectively and efficiently. MATERIAL AND METHODS: Through an analysis of the Osteoporosis in Internal Medicine (OSTEOMED) registry, this study presents the main clinical characteristics of patients with osteoporosis who attended internal medicine consultations in 23 Spanish hospital centres between 2012 and 2017. We analysed the reasons for the consultations, the densitometric values, the presence of comorbidities, the prescribed treatment and other lifestyle-related factors. RESULTS: In total, 2024 patients with osteoporosis were assessed (89.87% women, 10.13% men). The patients' mean age was 64.1±12.1 years (women, 64.7±11.5 years; men, 61.2±14.2 years). There was no significant difference between the sexes in their history of recent falls (9.1% and 6.7%); however, there were significant differences in the daily intake of calcium from milk products (553.8±332.6mg for women vs. 450.2±303.3mg for men; p<.001) and in the secondary causes of osteoporosis (13% of men vs. 6.5% of women; p<.001). In the sample, there were 404 fractures (20%), with a notable number of confirmed vertebral fractures (17.2%, 35.6% in men vs. 15.2% in women; p<.001). A large portion of the patients did not undergo the indicated treatment and presented low levels of physical activity and sun exposure. A significant percentage of the patients presented associated comorbidities, the most common of which were hypertension (32%) and dyslipidaemia (28%). CONCLUSIONS: These results define the profile of patients with osteoporosis who attend internal medicine consultations in Spain. The results also show the multisystemic character of this condition, which, along with its high prevalence, determine that the specific internal medicine consultations dedicated to managing the condition are the appropriate place for caring for these patients.

Hyperuricaemia as a prognostic factor for acute ischaemic stroke. / Uricemia como factor pronóstico del ictus isquémico agudo.

INTRODUCTION: Recent studies on uric acid as a biomarker for the prognosis of acute stroke have found conflicting results. METHODS: We collected blood samples from 600 consecutively admitted patients at our tertiary hospital and analysed the relationship between uric acid levels and functional prognosis (measured using the modified Rankin Scale [mRS]). Patients who had received reperfusion therapy were excluded since this may have influenced uric acid levels. RESULTS: A total of 73% of patients had mRS scores ≤2; the mean uric acid level was 5.22mg/dL. We found a nonlinear relationship between functional prognosis at discharge and serum uric acid levels at admission when the National Institutes of Health Stroke Scale score was excluded from the analysis. CONCLUSIONS: Serum uric acid levels in patients with acute ischaemic stroke are significantly associated with functional prognosis at discharge, although this relationship is nonlinear. In fact, poorer prognosis is associated both with very low and with very high concentrations of uric acid. This suggests a dual role of uric acid in relation to stroke: on the one hand, as an associated risk factor, and on the other, as a possible neuroprotective factor due to its antioxidant effect.

Profile of patients who visit medical internists for an osteoporosis assessment: The OSTEOMED registry. / Perfil de los pacientes que acuden al médico internista para valoración de osteoporosis: registro OSTEOMED.

BACKGROUND AND OBJECTIVES: Osteoporosis is considered a generalised skeletal disorder in which there is impaired bone resistance, which predisposes the individual to a greater risk of fracture. The aim of this cross-sectional study was to collect and present data on the main clinical characteristics of patients who consult medical internists in Spain. Understanding these characteristics can help in implementing action plans to improve these patients' care more effectively and efficiently. MATERIAL AND METHODS: Through an analysis of the Osteoporosis in Internal Medicine (OSTEOMED) registry, this study presents the main clinical characteristics of patients with osteoporosis who attended internal medicine consultations in 23 Spanish hospital centres between 2012 and 2017. We analysed the reasons for the consultations, the densitometric values, the presence of comorbidities, the prescribed treatment and other lifestyle-related factors. RESULTS: In total, 2024 patients with osteoporosis were assessed (89.87% women, 10.13% men). The patients' mean age was 64.1±12.1 years (women, 64.7±11.5 years; men, 61.2±14.2 years). There was no significant difference between the sexes in their history of recent falls (9.1% and 6.7%); however, there were significant differences in the daily intake of calcium from milk products (553.8±332.6mg for women vs. 450.2±303.3mg for men; P<.001) and in the secondary causes of osteoporosis (13% of men vs. 6.5% of women; P<.001). In the sample, there were 404 fractures (20%), with a notable number of confirmed vertebral fractures (17.2%, 35.6% in men vs. 15.2% in women; P<.001). A large portion of the patients did not undergo the indicated treatment and presented low levels of physical activity and sun exposure. A significant percentage of the patients presented associated comorbidities, the most common of which were hypertension (32%) and dyslipidaemia (28%). CONCLUSIONS: These results define the profile of patients with osteoporosis who attend internal medicine consultations in Spain. The results also show the multisystemic character of this condition, which, along with its high prevalence, determine that the specific internal medicine consultations dedicated to managing the condition are the appropriate place for caring for these patients.

Relationship between vitamin D deficiency and visually evoked potentials in multiple sclerosis. / Asociación entre el déficit de vitamina D y los potenciales evocados visuales en la esclerosis múltiple.

OBJECTIVE: To evaluate the possible relationship between serum 25-OH vitamin D levels and visually evoked potentials (VEP) in patients with multiple sclerosis (MS), residents in the south zone of Gran Canaria. MATERIAL AND METHODS: The study included 49 patients with MS, on whom 25-OH-vitamin D was determined, along with VEP, and a neurological examination to determine incapacity. Clinical variables, such as a history of optic neuritis were recorded. RESULTS: The mean value of 25-OH-vitamin D of the patients was 28.1±9.5ng/ml. The VEP latency was 119.1±23.2ms and the amplitude, 8.5±4.4 µV. Patients with a higher 25-OH-vitamin D had a greater number of outbreaks in the year prior to the study (P=.049), and those with vitamin D deficiency and previous optic neuritis showed no reduction in the amplitude of the VEP (P=.006). CONCLUSION: Patients with vitamin D deficiency have lower clinical activity of the MS and show no axonal involvement in VEP after having suffered optic neuritis. These relationships, although statistically significant, do not seem clinically plausible, thus new studies are needed to try and confirm this possible relationship.

[Evidenced based medicine and drugs approved for the treatment of osteoporosis. Role of calcium and vitamin D]. / La medicina basada en la evidencia y los fármacos aprobados para el tratamiento de la osteoporosis. Papel del calcio y la vitamina D.

Osteoporosis is a very common disease, which affects aged elderly people. Fractures are the main clinical manifestation of osteoporosis, being the more frequent fractures, vertebral fractures, distal forearm fractures and proximal femur fractures. The main objective in the treatment of osteoporosis is to avoid or to reduce new fractures. To obtain this, an integral approach should be done, including non-pharmacological measures, as a well balanced diet, the practising of regular exercise, avoiding or suppressing toxic habits (excess of alcohol and tobacco), and when indicated, patients should take a drug. There are several drugs available whose reduce the risk of fracture, all of them evaluated under the "Evidence-Based Medicine" criteria. Not all the drugs reduce the risk of all fracture. Thus, there are drugs that reduce only the risk of vertebral fractures, drugs that reduce the risk of non-vertebral fractures and finally, drugs that reduce the risk of hip fracture. All the studies performed on osteoporosis, the drugs have been always prescribed together with a supplement of calcium and Vitamin D. So, the correct prescription of a treatment for osteoporosis should include general measurements, the chosen drug and a supplement of calcium and Vitamin D.

[Guide for the prevention and treatment of glucocorticoid-induced osteoporosis of the Spanish Society of Internal Medicine]. / Guía de prevención y tratamiento de la osteoporosis inducida por glucocorticoides de la Sociedad Española de Medicina Interna.

Our objective has been to elaborate an updated Clinical Guide of the Spanish Society of Internal Medicine (SEMI) for the prevention and treatment of glucocorticoids-induced osteoporosis (GIO), identifying and measuring the grade of evidence that supports the given recommendations. For this, we reviewed studies performed on pathophysiology, diagnosis, prevention and treatment of GIO and after analyzing them we elaborated the present recommendations. This was done after a pre-specified and reproducible process that included an accepted model for the evaluation, and the reference of the evidence that supported it. Once the Scientific Committee elaborated the draft of the Clinical Guide, it was reviewed by all the members of the Working Group on Osteoporosis of the SEMI, and by an External Committee who included experts of many different specialities. Pathophysiology of GIO is complex and yet unknown. Bone effects of glucocorticoids are determined by multiple factors although accumulated doses seems to be the most important one. The best method to diagnose GIO is Dual X-Ray Absorptiometry (DXA), although WHO criteria defined for the diagnosis of postmenopausal osteoporosis are not applicable in GIO. The presence of a T-score lower than -1.5 Tscore indicates the necessity of treatment in any patient who receives or is going to receive more than 3 months treatment with glucocorticoids at a dose higher than 2.5 mg/day (in postmenopausal women) and 5 mg/day (in premenopausal women and men). DXA is also useful to follow up the patients, who can be done annually. Treatment must be prescribed to any patient who is receiving glucocorticoids or is going to receive them at doses higher than 7.5 mg/day for more than 3 months and 5 mg/day if the patient is a postmenopausal woman or has suffered from previous fragility fractures. Risedronate and alendronate are the drugs of election, always together with calcium and vitamin D supplements and general measurements usually prescribed in the treatment of osteoporosis. In very ill patients, parathyroid hormone can be used. The treatment for GIO should be maintained while glucocorticoid therapy is used.

[Prevalence of vertebral fractures in hip fracture patients]. / Prevalencia de fracturas vertebrales en pacientes con fractura de cadera.

BACKGROUND: Fractures are the clinical complication of osteoporosis. There are no previous studies that describe the prevalence of vertebral fractures (VF) in patients admitted into a hospital due to a hip fracture (HF). OBJECTIVE: To study the prevalence of vertebral fractures in elderly women in the moment of their admission to the hospital due to a hip fracture. METHOD: This is a cooperative, multicentric, case-control study, performed in 21 different hospitals of Spain by the Working Group on Osteoporosis of the Spanish Society of Internal Medicine. A total of 143 elderly women with hip fractures comprised the case group. The control group consists of 138 elderly women admitted into other wards of the hospital due to other diseases with no relationship with osteoporosis. A questionnaire was administered and a lateral thoracic and lumbar X-ray was performed to assess vertebral fractures applying Genant's criteria. RESULTS: The mean age of the patients with HF was 79.8 +/- 6.9 years and the mean age of the controls was 77.7 +/- 8.9 years. Patients suffering from HF had less weight than controls (BMI: 25.9 +/- 4.4 g/m2 vs 27.7 +/- 5.2 kg/m2, p = 0.002). Prevalence of VF was 62.6% in patients with HF, and 50% in controls (p = 0.039). CONCLUSIONS: Elderly women admitted to a hospital due to hip fracture have a very high prevalence of previously undiagnosed VF. Indeed, elderly women admitted into the hospital because of other diseases also have a high prevalence of VF. These facts must be taken into account due to the morbidity and mortality of VF, that increases the HF morbidity and mortality.

[Parathyroid hormone in the treatment of osteoporosis]. / La hormona paratiroidea en el tratamiento de la osteoporosis.

Current treatments available for osteoporosis until recently were active by inhibiting osteoclast activity and, thus, reducing bone remodelling. Intact PTH (PTH 1-84) and its analog, teriparatida (human recombinant PTH 1-34), are a new class of anabolic treatment of osteoporosis. It has been described a positive effect on bone microarchitecture and a reduction of the risk of new fractures due to a bone-forming mechanism.PTH must be considered as an useful alternative in the treatment of severe osteoporosis, both in men and women, in patients with several osteoporosis-related fractures or with a very low bone mineral density (T-score below -3.5) an a high risk for fracture. Other potential uses are glucocorticoid-induced and other secondary osteoporosis. The use of PTH is not recommended for more than 18 months for teriparatida and 24 months for PTH 1-84.

[Influence of the different bisphosphonates dose regimens on its tolerability]. / Influencia de los diferentes regímenes de administración de los bifosfonatos sobre la tolerabilidad.

Osteoporosis is the most prevalent metabolic bone disease and fractures are its clinical complication. We have nowadays some drugs that reduce the incidence of new fractures: Bisphosphonates. Nevertheless, treatment must be taken properly in the long run to reduce the incidence of new fractures and a few months alter starting the treatment, a great number of patients stop it because of different reasons. The introduction of new bisphosphonates that can be taken weekly or even better monthly, has improved notably the adherence and compliance to osteoporosis treatment.

[Estimation of vitamin supplements and minerals consumption dispensed through pharmacy offices in the province of Las Palmas]. / Estimación del consumo de suplementos vitamínicos y minerales dispensados a través de las oficinas de farmacia de la provincia de Las Palmas.

BACKGROUND: Vitamin supplements and minerals consumption (SPM) is increasing in occidental societies due to the growing concern about health by the population. OBJECTIVES: To have a initial approaching to the to SPM consumption in the Province of Las Palmas through 2000 and 2001. To identify SPM proportions that are dispensed as pharmaceutical specialities and those who are sold as parapharmacy products. Finally, to describe the evolution of this consumption throughout a year. METHOD: The information was obtained through the list of the whole pharmaceutical specialities and parapharmacy products through 2000 and 2001 who have at least a vitamin in its composition and/or a mineral. RESULTS: Usually, 297 pharmaceutical specialities and 216 parapharmacy products are currently being sold. Pharmaceutical specialities comprised 65.6% of the whole products sold and within them, vitamins were the most dispensed (41.5%). Regarding parapharmacy products, vitamins and minerals compounds were the products more sold (34.6%). Comparing to 2000, during 2001 there was a statistically significant increase in the consumption of parapharmacy products, remaining without changes the use of pharmaceutical specialities. CONCLUSION: On the basis of sold XX SPM consumption seems to be due mainly by pharmaceutical specialities rather than parapharmacy products. Nevertheless through 2001 there was an increase only in the parapharmacy products.

[What is the opinion of Spanish internists on osteoporosis?]. / 'Qué opinan los internistas españoles de la osteoporosis?

OBJECTIVE: To conduct an opinion survey on osteoporosis in Spanish internists. METHOD: Survey sent by mail and by personal visit to members of the Spanish Internists Society. Collection of data on opinion on the disease, diagnostic and therapeutic attitude and means available (general laboratory analyses, conventional radiology, biochemical markers of bone remodeling, densitometry and ultrasounds) and preference when choosing a certain treatment. RESULTS: A total of 538 internists answered. More than 90% of those surveyed consider that osteoporosis is a disease that should be treated by internists. A total of 93% consider that osteoporosis is a prevalent disease. More than 80% have access to densitometry. CONCLUSIONS: The majority of Spanish internists consider that osteoporosis is a disease that should be treated by internists and that it is a disease that enters into their action scope. In general, they have the means necessary for its study and treatment. Bisphosphonates constitute the drug of choice and calcium and vitamin D supplements are indicated in almost all the cases.